MedTrace Logo

Safety and Efficacy Study of Adjunctive Antiplatelet Therapy Prior to Primary PCI in Patients With STEMI

NCT00546260 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2023-08-16

Study results available
· View outcomes & findings →

Summary

Safety and efficacy of adjunctive antiplatelet therapy prior to primary percutaneous intervention (PCI) in patients with ST-Elevation Myocardial Infarction (STEMI)

Conditions

Interventions

DRUG

placebo

administration of iv bolus prior to angiography

DRUG

PRT060128 Potassium

administration of iv bolus prior to angiography

Sponsors & Collaborators

  • Portola Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Matthew T. Roe, MD, MHS · Duke Clinical Research Institute

  • Michael Gibson, MD, MS · PERFUSE Angiographic Core Laboratory and Data Coordinating Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-30
Primary Completion
2008-07-31
Completion
2008-07-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00546260 on ClinicalTrials.gov